TRIM33 and breast carcinoma: Among anti-TIF1γ(+) patients with malignancy (n=12), 4 cases had breast cancer, 2 lung cancer, 1 colorectal, 1 ovarian, 1 prostate, 1renal cell and 1 bladder urothelial carcinoma and 1 oropharyngeal carcinoma.